Cannabidiol as a new treatment for drug‐resistant epilepsy in tuberous sclerosis complex
Tuberous sclerosis complex (TSC) is an autosomal‐dominant genetic disorder with highly variable expression. The most common neurologic manifestation of TSC is epilepsy, which affects approximately 85% of patients, 63% of whom develop treatment‐resistant epilepsy. Herein, we evaluate the efficacy, safety, and tolerability of cannabidiol (CBD), a nonpsychoactive compound derived from the marijuana plant, as an adjunct to current antiepileptic drugs in patients with refractory seizures in the setting of TSC.
No Supplementary Data
No Article Media